Compare GNSS & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNSS | CNTB |
|---|---|---|
| Founded | 1992 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.0M | 135.7M |
| IPO Year | 1996 | 2020 |
| Metric | GNSS | CNTB |
|---|---|---|
| Price | $1.65 | $2.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.75 | ★ $8.67 |
| AVG Volume (30 Days) | 85.8K | ★ 635.1K |
| Earning Date | 05-11-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.44 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $26,306,790.00 | $64,000.00 |
| Revenue This Year | $80.08 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 29.50 | N/A |
| 52 Week Low | $1.40 | $1.23 |
| 52 Week High | $2.70 | $3.82 |
| Indicator | GNSS | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 42.61 | 44.00 |
| Support Level | $1.57 | $2.10 |
| Resistance Level | $2.02 | $2.75 |
| Average True Range (ATR) | 0.12 | 0.22 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 1.47 | 6.76 |
Genasys Inc is a provider of Protective Communication solutions, including Genasys Protect software platform and Long Range Acoustic Device (LRAD). Its software platform receives information from variety of sensors and Internet-of-Things (IoT) inputs to collect real-time information on developing and active emergency situations. Genasys uses this information to create and disseminate alerts, warnings, notifications, and instructions through multiple channels before, during, and after public safety and enterprise threats, critical events, and other crisis situations. The Company operates in two business segments: Hardware and Software and its markets are North and South America, Europe, Middle East and Asia. Key revenue is generated from Hardware.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.